Intravitreal triamcinolone acetonide for diabetic macula edema

Israel Medical Association Journal

Volumn 8, Issue 6, 2006, Pages 426-427

  Loewenstein, Anat ^a,b   Goldstein, Michaella ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Diabetic macular edema; Foveal thickness; Intravitreal triamcinolone; Visual acuity

Indexed keywords

TRIAMCINOLONE ACETONIDE;

CATARACT; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ENDOPHTHALMITIS; HUMAN; INTRAOCULAR HYPERTENSION; OUTCOME ASSESSMENT; VISUAL IMPAIRMENT;

DIABETIC RETINOPATHY; DRUG ADMINISTRATION SCHEDULE; HUMANS; MACULAR EDEMA, CYSTOID; MICROINJECTIONS; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 33745632024     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (22)

1. Desatnik H, Habot-Wilner Z, Alhalel A, Moroz I, Glovinsky J, Moisseiev J. The transient efficacy of a single intravitreal triamcinolone acetonide injection for diabetic macular edema. IMAJ 2006;8:383-7.
2. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV: Diabetic macular edema. Ophthalmology 1984;91:1464-74.
3. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001;132:425-7.
4. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61.
5. Jonas JB, Harder B, Kamppeter BA. Inter-eye difference in diabetic macular edema after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2004;138:970-7.
6. Jonas JB, Degenring RF, Kamppeter BA, Kreissig I, Akkoyun I. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 2004;138:158-60.
7. Sutter FKP, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment. Ophthalmology 2004;111:2044-9.
8. Chieh JJ, Roth D, Liu M, et al. Intravitreal triamcinolone acetonide for diabetic macular edema. Retina 2005;25:828-34.
9. Barak A, Regenbogen M, Goldstein M, Loewenstein A. Intravitreal triamcinolone injection for diffuse diabetic macular edema with foveal cystoid changes. IMAJ 2006;8:83-7.
10. Lam DSC, Chan CKM, Tang EWH, et al. Intravitreal triamcinolone for diabetic macular oedema in Chinese patients: six-month prospective longitudinal pilot study. Clin Exp Ophthalmol 2004;32: 569-72
11. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-7.
12. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema - preliminary results of a prospective controlled trial. Ophthalmology 2004;111: 218-25.
13. Spandau UHM, Derse M, Schmitz-Valckenberg P, Papoulis C, Jonas B. Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br J Ophthalmol 2005;89:999-1003.
14. Jonas JB, Akkoyun I, Kreissig I, Degenring RF. Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study. Br J Ophthalmol 2005;89:321-6.
15. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005;140:695-702.
16. Patelli F, Fasolino G, Radice P, et al. Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macular edema with and without previous macular laser treatment. Retina 2005;25:840-5.
17. Jonas JB, Martus P, Degenring RF, Kreissig I, Akkoyun I. Predictive factors for visual acuity after intravitreal triamcinolone treatment for diabetic macular edema. Arch Ophthalmol 2005;123:1338-43.
18. Audren F, Tod M, Massin P, et al. Pharmacokinetic-pharmacodynamic modelling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 2004;45:3435-41.
19. Jonas JB, Degenring R, Kreissig I, Akkoyun I. Safety of intravitreal high-dose reinjections of triamcinolone acetonide. Am J Ophthalmol 2004;138:1054-5.
20. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003; 87:24-7.
21. Nelson ML, Tennant MT, Sivalingam A, Regillo CD, Belmont JB, Martidis A. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2005;23:686-91.
22. Jonas JB, Kreissig I, Spandau UH, Harder B. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am J Ophthalmol 2006;141:579-80.